N-[4-methoxy-3-(naphthylmethoxy)phenyl]-2-naphthylethanamide | 444343-25-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[4-methoxy-3-(naphthylmethoxy)phenyl]-2-naphthylethanamide
• 英文别名: N-[4-methoxy-3-(naphthalen-1-ylmethoxy)phenyl]-2-naphthalen-1-ylacetamide
• CAS: 444343-25-3
• 化学式: C₃₀H₂₅NO₃
• 分子量: 447.533
• InChiKey: IGIRCFLGTAOSLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Trisubstituted carbocyclic cyclophilin binding compounds and their use
  申请人：——

  公开号：US20020165275A1

  公开（公告）日：2002-11-07

  The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.

  本发明涉及一种新型的非肽类小有机化合物，其具有与环肽亚精蛋白（CyP）型免疫蛋白亲和力，并且涉及包含所述化合物中的一个或多个的药物组合物。该发明还涉及这些化合物和组合物用于结合CyP型蛋白，抑制其肽基脯氨酸异构酶活性，并在各种医学疾病的研究、开发和治疗应用中的用途。
• TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1360173A2

  公开（公告）日：2003-11-12
• US6656971B2
  申请人：——

  公开号：US6656971B2

  公开（公告）日：2003-12-02
• [EN] TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSES DE LIAISON DE LA CYCLOPHILINE CARBOXYLIQUE TRISUBSTITUEE ET LEUR UTILISATION
  申请人：GUILFORD PHARM INC

  公开号：WO2002059080A2

  公开（公告）日：2002-08-01

  The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.